Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer

被引:0
|
作者
Labanaris, Apostolos P. [1 ]
机构
[1] Interbalkan Med Ctr, Dept Urol, Thessaloniki, Greece
来源
JOURNAL OF UROLOGY | 2013年 / 189卷 / 03期
基金
英国医学研究理事会;
关键词
biopsy; magnetic resonance imaging; prostate; prostatic neoplasms; risk;
D O I
10.1016/j.juro.2012.10.133
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Multiparametric magnetic resonance imaging can be used to guide prostate biopsy by targeting biopsies to areas in the prostate at high risk for cancer. We compared the detection of clinically significant and insignificant cancer by transperineal magnetic resonance imaging targeted biopsy and transperineal template guided prostate biopsy. Materials and Methods: A total of 182 men with a lesion suspicious for cancer on multiparametric magnetic resonance imaging underwent transperineal magnetic resonance imaging targeted biopsy using a cognitive registration technique, followed by systematic transperineal template guided prostate biopsy. The primary outcome was the detection rate of clinically significant prostate cancer. Clinical significance was defined using maximum cancer core length 4 mm or greater and/or Gleason grade 3 + 4 or greater (University College London definition 2). We secondarily evaluated other commonly used thresholds of clinically significant disease, including maximum cancer core length 6 mm or greater and/or Gleason grade 4 + 3 or greater, maximum cancer core length 3 mm or greater and/or Gleason grade 3 + 4 or greater, and maximum cancer core length 2 or greater mm and/or Gleason grade 3 + 4 or greater. Strategies were statistically compared with the McNemar test. Results: Mean +/- SD patient age was 63.3 +/- 7.2 years. Median prostate specific antigen was 6.7 ng/ml (IQR 4.7-10.0). Clinically significant cancer was detected by magnetic resonance imaging targeted biopsy and template guided prostate biopsy in 103 (57%) and 113 of the 182 men (62%) (p = 0.174), and clinically insignificant cancer was detected in 17 (9.3%) and 31 (17.0%), respectively (p = 0.024). Conclusions: Prostate biopsy targeted to suspicious lesions on multiparametric magnetic resonance imaging has encouraging rates of detection of clinically significant cancer while also decreasing the detection rate of clinically insignificant cancer. This is achieved with fewer biopsy cores than for systematic template guided biopsy. Further prospective, multicenter, comparative trials of the performance of targeting strategies are needed to consider magnetic resonance imaging targeted biopsy an alternative to conventional systematic biopsy.
引用
收藏
页码:866 / 866
页数:1
相关论文
共 50 条
  • [21] Value of MRI-targeted prostate biopsy in addition to systematic transperineal biopsy for detection of prostate cancer
    Uno, Hiromi
    Saito, Akihiro
    Toyota, Syohei
    Takada, Toshihiko
    Komeda, Hisao
    Nakano, Masahiro
    Deguchi, Takashi
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A166 - A167
  • [22] Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer
    Valerio, Massimo
    McCartan, Neil
    Freeman, Alex
    Punwani, Shonit
    Emberton, Mark
    Ahmed, Hashim U.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (10) : 424.e9 - 424.e16
  • [23] Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy
    Kaufmann, Basil
    Saba, Karim
    Schmidli, Tobias S.
    Stutz, Stephanie
    Bissig, Leon
    Britschgi, Anna Jelena
    Schaeren, Evodia
    Gu, Alexander
    Langenegger, Nicole
    Sulser, Tullio
    Eberli, Daniel
    Keller, Etienne X.
    Hermanns, Thomas
    Poyet, Cedric
    PROSTATE, 2022, 82 (03): : 388 - 396
  • [24] A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk
    Miah, Saiful
    Hosking-Jervis, Feargus
    Connor, Martin J.
    Eldred-Evans, David
    Shah, Taimur T.
    Arya, Manit
    Barber, Neil
    Bhardwa, Jeetesh
    Bott, Simon
    Burke, Daniel
    Doherty, Alan
    Foster, Christopher
    Freeman, Alex
    Hindley, Richard
    Jameson, Charles
    Karim, Omer
    Laniado, Marc
    Montgomery, Bruce
    Nigam, Raj
    Punwani, Shonit
    Sinclair, Andrew
    Winkler, Mathias
    Allen, Clare
    Ahmed, Hashim U.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 262 - 269
  • [25] Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial
    Mian, Badar M.
    Feustel, Paul J.
    Aziz, Asef
    Kaufman Jr, Ronald P.
    Bernstein, Adrien
    Fisher, Hugh A. G.
    JOURNAL OF UROLOGY, 2024, 212 (01): : 21 - 31
  • [27] Prostate cancer detection rate with MRI-targeted biopsy alone using outpatient transperineal prostate biopsy
    Avolio, P. P.
    Hassan, T.
    Addar, A.
    Alshamsi, H.
    Mcpherson, V
    Loutochin, O.
    Anidjar, M.
    Sanchez-Salas, R.
    EUROPEAN UROLOGY, 2024, 85 : S758 - S758
  • [28] Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer EDITORIAL COMMENT
    Dominguez-Escrig, Jose L.
    JOURNAL OF UROLOGY, 2018, 200 (02): : 317 - 318
  • [29] Significant impact of transperineal template biopsy of the prostate at a single tertiary institution
    Huang, Sean
    Reeves, Fairleigh
    Preece, Jessica
    Satasivam, Prassannah
    Royce, Peter
    Grummet, Jeremy P.
    UROLOGY ANNALS, 2015, 7 (04) : 428 - 432
  • [30] Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach
    E J Bass
    I A Donaldson
    A Freeman
    C Jameson
    S Punwani
    C Moore
    M Arya
    M Emberton
    H U Ahmed
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 311 - 317